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ABSTRACT 
 
Objectives: To determine the outcome of an expanded cohort of patients with relapsed 
germ cell tumors (GCT) treated with a salvage chemotherapy regimen consisting of 
irinotecan, paclitaxel and oxaliplatin (IPO) and assess the role of IPO as an alternative to 
standard cisplatin-based chemotherapy regimens in this setting.  
Patients and methods: The results of 72 consecutive patients were reviewed 
retrospectively.  IPO was used either as a second-line treatment (n=29), of which 20 patients 
subsequently received high-dose chemotherapy (HDCT), or third-line (n=43), of which 32 
patients proceeded to HDCT.  
Results: The 2-year PFS and 3-year OS rates for the whole cohort were 30.2% (95%CI 
17.3-40.5%) and 33.4% (95%CI: 20.1-43.8 %) respectively. CR was achieved in 3%, m-ve 
PR in 41%, m+ve PR in 18%, SD in 17% and PD in 20%. In the second-line setting, the 2-
year PFS rate was 43.5% (95%CI: 21.7-60.8%) and 3-year OS 49.1% (95%CI: 24.2-65.1%). 
In the third-line setting, the 2-year PFS rate was 21.0% (95%CI 9.5-35.4%) and the 3-year 
OS rate was 23.9% (95%CI 11.7-38.2).According to the current international prognostic 
factor study group criteria for first relapse for the high and very high risk group the 2 year 
PFS rates were 50% and 30% respectively. There were 2 treatment related deaths from 
IPO, and 4 from HDCT. Grade 3 or 4 toxicities included neutropenia (35%), 
thrombocytopenia (18%), infection (15%), diarrhea (11%) and lethargy (8%).   
Conclusions: IPO offers an effective, well-tolerated, non-nephrotoxic alternative to cisplatin-
based salvage regimens for patients with relapsed GCT. It appears particularly useful in high 
risk patients and for those in whom cisplatin is ineffective or contra-indicated. 
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Introduction:  
 
The most frequently used management approach for patients with relapsed germ cell tumors 
involves cisplatin-based induction regimens given with ifosfamide and a third drug (e.g. 
etoposide [1], vinblastine [2] or paclitaxel [3]), this may be followed by consolidation with high 
dose chemotherapy (HDCT) and peripheral blood stem cell (PBSC) rescue. An alternative 
has been to mobilize stem cells with conventional chemotherapy and proceed to sequential   
HDCT regimens usually containing intensified carboplatin and etoposide, although thiotepa 
or cyclophosphamide have been included in some series. Sequential high dose 
chemotherapy and may be less toxic and more effective [4], although the improvement in 
survival seems more to do with the reduction  in treatment related toxicity rather than an 
improvement in tumour control when compared to a single cycle of  carboplatin etoposide 
and cyclophosphamide. [4] 
 
Both conventional-dose chemotherapy (CDCT) and HDCT are used in patients with 
metastatic germ cell tumors at first relapse, although it remains uncertain as to which is the 
most effective treatment strategy. A recent retrospective analysis of a large cohort of 
patients with metastatic GCTs at first relapse suggested a significant improvement in 
progression-free survival (PFS) and overall survival (OS) associated with intensified HDCT 
compared to CDCT in most prognostic groups [5]. These results are consistent with a large 
single-center analysis but challenge the results from the IT94 study, a prospective 
randomized trial that found no benefit from HDCT compared with CDCT in the first salvage 
setting [6, 7]. Currently there is no clear consensus on the optimal chemotherapy for patients 
with GCTs at second relapse, or those with mediastinal primaries at first relapse, who 
usually have very poor outcomes [8]. 
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The efficacy of IPO (irinotecan, paclitaxel and oxaliplatin) in patients with relapsed GCTs 
was first described in a Phase II study of 28 patients in 2006 [9]. IPO offers a different side 
effect profile than cisplatin-based regimens and was used in patients with GCTs who 
relapsed despite two prior lines of cisplatin–based chemotherapy or in patients with primary 
mediastinal GCTs who relapsed after first-line cisplatin-based treatment.  
 
Following this study, our network of hospitals adopted this protocol and has continued to 
administer it in this therapeutic setting. We have extended its use in the first salvage setting 
to include patients who are over the age of 35 and those who had raised levels of lactate 
dehydrogenase (LDH), a poor prognosis marker, at relapse [10]. The updated results 
presented here include all patients treated with this protocol at our institutions between 2001 
and 2011. 
 
Patients and methods: 
Between March 2001 and September 2011, 72 patients were treated with IPO +/- HDCT 
using Thiotepa, carboplatin and topotecan. The intention was to proceed to high dose 
chemotherapy as consolidation of IPO unless  either an insufficient number of stem cells 
were collected or the patient were deemed not fit enough to proceed due to poor 
performance status or rapidly progressive disease.Twenty-nine patients received IPO 
second-line, of whom 20 proceeded to consolidation with HDCT. Forty-three patients 
received IPO third-line, of whom 33 proceeded to HDCT. Patients who received IPO in the 
second-line setting had failed one platinum-based therapy and either had a mediastinal non-
seminomatous GCT (NSGCT), or a raised LDH at relapse or were over the age of 35. 
Patients who received IPO in the third-line setting had failed two cisplatin-based 
chemotherapy regimens. 
 
Treatment responses were measured using the same criteria described in our previous 
phase II study, which are in keeping with other published reports. Progressive disease (PD) 
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was defined as the development of new sites of disease with rising tumor markers if present. 
Stable Disease was defined as the lack of any new sites of disease and a <90% reduction in 
tumor markers, 28 days post-chemotherapy. Marker-positive partial response (M+ve PR) 
was defined as a >90% reduction in tumor markers (without normalisation) for >28 days, and 
no new sites of disease. Marker-negative partial response (M-ve PR) was defined as a 
normalisation of tumor markers and no new sites of disease for at least 28 days. For those 
patients who had normal tumor markers before chemotherapy, an M-ve PR required a 50% 
reduction in the bidimensional measurements of the residual masses to be maintained for at 
least 28 days. Complete remission (CR) was defined as a normalisation of tumor markers 
with a complete resolution of all sites of disease. Postsurgical outcome was defined as 
outcome following surgery performed to remove all sites of disease, and patients who 
achieved a radiological CR to chemotherapy alone or had a surgically induced CR were 
deemed to have no evidence of disease (NED). Platinum sensitivity prior to high-dose 
chemotherapy was defined according to the method described by Beyer [11] although it 
should be noted that in this study, treatment prior to high-dose therapy was oxaliplatin-based 
rather than cisplatin-based.  
 
Regimen: (Supplementary Figure A) 
IPO consisted of a 3-weekly regimen of irinotecan 200mg/m2 and oxaliplatin 100mg/m2 given 
on D1, and paclitaxel 80 mg/m2 administered on D1, D8 and D15. Two cycles were given 
and patients who showed evidence of response were given two further cycles. Filgrastim 
300mcg/day was given on alternate days from day 2 to day 14. 
 
Mobilisation of autologous blood stem cells was achieved using Paclitaxel 300mg/m2 over 24 
hours, followed 48 hours after initiation, by filgrastim 5mcg/kg/day given daily until day 10 
when a CD34 peripheral blood count was measured. Patients who had at least 8 CD34 
cells/microlitre proceeded to cell collection whilst those who had less were given a further 
dose of filgrastim and assessed the following day. A minimum of 1x106 CD 34 cells /kg were 
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required to proceed to HDCT. Normally stem cell collection was attempted prior to starting 
IPO but in those where urgent therapy was required, it was deferred until treatment was 
completed. The median CD34 cells harvested was 5.08 X106 cells/kg (range 1.11-43.02 X 
106 cells/kg) and the median interval between mobilization and harvesting was 10 days 
(range 3-21 days). 
 
Patients with at least M+ve PR proceeded to high dose chemotherapy consisting of 
carboplatin AUC7 followed 12 hours later by topotecan 10 mg/m2 on D1, D2 and D3. 
Thiotepa was given as a continuous infusion on D1-D4 at 125mg/m2/day. Autologous blood 
stem cells were re-infused 2 days later. We selected this high dose to intensify topo-
isomerase 1 targeting and increase penetration through the blood-brain barrier. 
 
Statistical analysis: 
Survival curves are shown using Kaplan-Meier method. *** 
 
Results: 
The median follow up was 48.3 months ( range 7.7-150.7) , 2 patients were lost to follow up.  
Twenty-nine patients received IPO as the first salvage treatment of which 20 proceeded to 
HDCT with topotecan, carboplatin and thiotepa. Eleven patients went on to have surgery, 
and histological evaluation revealed necrosis in 5 patients, mature teratoma in 3 patients, 
and viable cancer in 3 patients. Nineteen patients (66%) had favourable responses, which 
included CR (N=6), NED following surgery (N=4) and M-ve PR (N=9) (Table 2). Of those 
patients with primary mediastinal GCTs, 8 (62%) had favorable responses (Table 2). 
According to the International Prognostic Factors Study  Group criteria (IPFSG),the PFS 
rates at 2 years and the overall survival rates at 3 years for patients treated at their first 
relapse were 56.6% and 43.8% respectively for intermediate risk patients, 50% and 83.3% 
respectively for high risk patients, and 30% each for very high risk patients (Supplementary 
Table A). 
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Forty-three patients received IPO at their second relapse, of which 32 proceeded to HDCT 
and 6 subsequently received surgery. Twenty-one patients (49%) achieved a favorable 
response including CR (N=3), NED after surgery (N=3) and M-ve PR (N=15) as shown in 
Table 2. The 2-year PFS and 3-year overall survival were 21.0% and 23.9% respectively for 
this group of patients. Histological evaluation of surgically resected disease showed necrosis 
in 3 patient samples and viable cancer in the other 3, one of which demonstrated primitive 
neuroectodermal transformation.  
 
Applying the Beyer’s HDCT prognostic prediction, the 2-year PFS rates for patients in this 
study were 52%, 29% and 0% for the good, intermediate and poor risk groups respectively. 
The 3-year OS rates were 63%, 10% and 0% for the good, intermediate and poor risk 
groups respectively (Figure 2). 
  
Toxicity 
Toxicities from IPO and HDCT are shown in Supplementary Tables B & C respectively. 
There were two treatment related deaths associated with IPO, both due to neutropenic 
sepsis. Three treatment related deaths were associated with HDCT with topotecan, 
carboplatin and thiotepa which were due to staphylococcal sepsis in one patient, ARDS 
secondary to neutropenic sepsis in another, and fungal infection and liver failure in the third. 
Another treatment related death, secondary to mesenteric infarction, occurred in a patient 
who received a HDCT containing carboplatin/etoposide, having opted to receive this 
treatment at their local institution.  
 
Discussion: 
These results follow on from, and are consistent with, earlier data published in our original 
phase II study [9]. They strongly suggest that IPO can be used to achieve high response 
rates in patients with relapsed germ cell tumors, even in those with the most adverse risk 
factors for disease progression.  
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There is much debate as to which is the most effective CDCT regimen at first relapse, 
although TIP (cisplatin, ifosfomide, paclitaxel) has been adopted by many centers. 
Furthermore, whether HDCT should be routinely adopted as a first salvage modality, and if 
so, whether this should involve single or tandem transplantations remains uncertain. It is 
therefore unsurprising that there is no convention as to which regimen should be 
administered following further relapses. Issues surrounding specific toxicities and drug 
resistance related to the repeated use of cisplatin in such regimens have led to the search 
for other agents on which to base salvage therapies. This has involved exploring drugs of a 
similar class and those with different mechanisms of action that are relevant to GCT biology. 
Oxaliplatin is a third-generation diammine cyclohexane derivative with evidence of non-
cross-resistance to cisplatin. Various agents have been combined with it in the treatment of 
GCTs, and doublets using paclitaxel and irinotecan have shown similar efficacy. In the initial 
monotherapy studies in heavily pre-treated patients, paclitaxel showed moderate activity [12] 
and irinotecan [13] showed none; although most patients were heavily pre-treated. Based on 
this apparent lack of activity as a single agent, the contribution of irinotecan in the IPO 
regimen may questionable. However, there is histochemical evidence supporting the validity 
of topo-isomerase-1 targeting in GCTs [14] and the increased response rates described 
following the addition irinotecan to oxaliplatin therapy supports its role in this therapeutic 
context [15]. The use of paclitaxel in the IPO regimen is supported by previous data 
demonstrating long-term progression-free survival rates of 29% in patients with relapsed 
GCTs who received TI/CE [16]. 
 
The management of patients with relapsed mediastinal NSGCTs has proved particularly 
difficult. Poor responses to induction therapy have led to the exclusion of this group of 
patients from subsequent high dose treatments and surgical approaches are usually 
adopted instead. None of the patients with relapsed mediastinal NSGCTs in our cohort were A
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amenable to surgical resection, either due to metastases or tumor size and location. 
Nevertheless, our data suggest that IPO is an effective regimen in this patient group.  
 
There are inherent weaknesses in any retrospective study, particularly in a rare tumor type. 
In this study there was some heterogeneity of the patient groups and line of therapy, 
however the fact that follow up is complete and that our results mirror those reported in our 
original phase II study are re-assuring, The recent IPFSG criteria of prognostication at first 
relapse also add strength to the argument that salvage therapy for this patient group may be 
safely undertaken using non cisplatin-based approaches [17].  
 
Salvage therapy in germ cell tumors has been dominated by phase II studies and attempts 
to conduct phase III randomized trials have, to-date, been undermined by poor recruitment 
and under powering. We suggest that IPO can overcome problems associated with cisplatin 
resistance and toxicity by utilizing drugs that target cellular mechanisms shown to be 
important in GCT biology. IPO therefore appears to be an appropriate salvage therapy for 
routine use in patients with relapsed GCTs and high IPFSG scores including those with 
mediastinal NSGCTs. 
 
Conflicts of interest: None declared 
We would like to thank the Orchid Cancer Appeal for their  financial support of nursing staff 
involved in treating these patients. 
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Tables and figures: 
 
Figures 
 
Figure 1: progression-free and overall survival after 1st and 2nd relapse. 
Figure 2: outcome based on pre-high dose chemotherapy prognostic factors (Beyer HD 
prognostic categories). 
 
Supplementary Figure A: summary of regimen and stem cell collection procedure. 
Supplementary Figure B: outcome of patients with mediastinal disease. 
 
 
Tables 
 
Table 1: characteristic of patients receiving IPO chemotherapy at first and relapse. 
 
Table 2: outcome of patients receiving IPO at first and second relapse. 
 
Supplementary Table A: Progression free and overall survival by IPFSG criteria at first 
relapse. 
 
Supplementary Table B: Toxicity on IPO. 
 
Supplementary Table C: Toxicity on High Dose Topotecan, Carboplatin and Thiotepa. 
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Table 1: Characteristics of patients receiving IPO at first and second relapse 
 First Relapse (N=29) Second Relapse (N=43) 
Median age (range) 33 (17-74) 37 (18-65) 
IPFSG at diagnosis 
 Good 
 Intermediate 
 Poor 
 Unknown 
 
6 
5 
18 
N/A 
 
15 
13 
7 
8 
Histology 
 NSGCT 
 Seminoma 
 
26 
3 
 
37 
6 
Primary site 
 Testis 
 Mediastinum 
 Retroperitoneal 
 Extragonadal 
 Unknown 
 
13 
13 
2 
N/A 
1 
 
39 
N/A 
1 
3 
N/A 
Platinum sensitivity 
 Sensitive 
 Refractory 
 Absolutely refractory 
 Not applicable 
 
26 
1 
1 
1 
 
35 
4 
4 
N/A 
IPFSG at relapse 
 Low risk 
 Intermediate risk 
 High risk 
 Very high risk 
 
5 
8 
6 
10 
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Table 2: Outcome of patients at first and second relapse (mGCT: mediastinal GCT). 
 
 IPO IPO+HD 
 
Final 
 
 First  
Relapse 
N=29 (%) 
Second 
Relapse 
 N=43 (%) 
First 
Relapse 
N=20 (%) 
Second 
Relapse 
N=32 (%) 
First  
Relapse  
N=29 (%) 
Second 
Relapse 
N=43 (%) 
     All 
N=29 
mGCT 
N=13 
 
 
Response        
CR 1 (3.4) 1 (2.3) 5 (25) 
 
3 (9.4) 6 (20.7) 2 (15.4) 3 (7) 
NED (after 
surgery) 
1 (3.4) 0 3 (15) 3 (9.4) 4 (13.8) 1 (7.7) 3 (7) 
M-ve PR 9 (31.1) 19 (44.2) 8 (40) 10 (31.2) 9 (31) 5 (38.5) 15 (34.8) 
M+ve PR 9 (31.1) 6 (14) 0 4 (12.5) 2 (6.9) 1 (7.7) 4 (9.3) 
SD 4 (13.8) 6 (14) 1 (5) 7 (21.9) 1 (3.4) 1 (7.7) 7 (16.3) 
PD 5  (17.2) 9 (20.9) 1 (5) 3 (9.4)  5 (17.3) 3 (23) 7 (16.3) 
TRD 0 2 (4.6) 2 (10) 2 (6.2) 2 (6.9) 0 4 (9.3) 
Favorable 
response rate 
(CR+NED+M-VE 
PR) 
                                         
19 (66) 
 
8 (62) 
 
21 (49) 
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FIGURE 1 
 
First relapse – Progression free survival 
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FIGURE 2 
 
Progression free survival 
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